rxpertusa logo spacer rxpertusa wings
logo spacer spacer spacer
spacer home
about us
assessment tools
sample consult
contact us
favorite links

red line

spacer spacer news

The latest Mainline newsletters for the General Public are listed here.


For healthcare professionals we have a Mainline newsletter in a Professional version here.

Printer Friendly


Volume 3 April 28, 2006 Number 2

An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate

Medication News & Update

Plavix Plus Aspirin in the News

Clopidogrel plus aspirin not beneficial (and possibly harmful) in a broad population with cardiovascular disease or with high risk of cardiovascular disease

The CHARISMA investigators conducted a prospective, multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of clopidogrel (75 mg per
day) plus aspirin (75 to 162 mg per day) compared with aspirin alone. The broad population included 15,603 patients with either clinically evident cardiovascular disease ("symptomatic") or multiple risk factors ("asymptomatic").... for more information see


1. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; DOI:10.1056/NEJMoa060989.



Home ] [ About Us  ] [ Assessment Tools  ] [ Sample Consult  ]
Contact Us  ] [ Favorite Links  ]

Copyright © www.rxpertusa.com. Designed by PcHousekeeping.com
  spacer spacer